ROWAN: An Open-Label, Prospective, Multi-Center, Randomized Clinical Trial To Evaluate The Efficacy and Safety Of TheraSphere followed by Durvalumab (Imfinzi?) With Tremelimumab, Versus TheraSphere Alone For Hepatocellular Carcinoma (HCC)
|Effective start/end date||7/1/22 → 6/30/26|
- Boston Scientific Corporation
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.